Month: May 2021
-
Synthetic Bio Company Goes Public in $2.5B Merger
A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition.
-
MD Anderson, Broad Institute Partner on Rare Cancers
MD Anderson Cancer Center and the Broad Institute are developing a new research platform for better understanding rare types of cancer.
-
New Biotech Developing Synthetic Long-Term RNA
A new enterprise, created by a life science venture capital company, began work on developing therapies with long-acting synthetic RNA.
-
Infographic – Public Money Funds Covid-19 Vaccines
As the race to produce and distribute Covid-19 vaccines intensifies, financing of this global public health project is starting to emerge.
-
Biotechs Partner on Gene-Edited Cancer Cell Therapies
Two biotechnology companies are collaborating on using the gene editing technique Crispr to create engineered immune-system cells to treat cancer.
-
AI Gene Therapy Platform Gains $100M in Early Funds
A company using machine learning to create engineered viruses to deliver gene therapies is raising $100 million in its first venture funding round.
-
Cell Therapy Mfring Company Raises $82M in Venture Funds
A company developing an automated yet personalized manufacturing platform for cell therapies is raising $82 million in its second venture funding round.
-
Antibody Clears Covid-19 Variants, Enters Trial
A synthetic antibody is shown in lab tests to neutralize variants of the SARS-CoV-2 virus, and will be added to an ongoing clinical trial of Covid-19 therapies.
-
Moderna Supplying 500M Vaccine Doses to Covax
Moderna Inc. is providing up to 500 million doses of its Covid-19 vaccine to the Covax Facility, an international project distributing vaccines to low-income countries.